If You Invested $1,000 in Cytek Biosciences, Inc. (CTKB)
This article analyzes the historical performance of investing $1,000 in Cytek Biosciences, Inc. (CTKB), a cell analysis solutions company. It details how such an investment would have fared over one year, highlighting a 35% return. The piece also provides an overview of Cytek Biosciences, its full spectrum profiling technology, products, customer base, geographic footprint, and public company status.
Cytek Biosciences explores growth paths as investors weigh long-term potential
Cytek Biosciences (CTKB, US23284C1053) is a life sciences company developing advanced instruments for cell analysis, particularly focusing on multi-parameter flow cytometry systems. The article highlights that with a thin news cycle, investor attention is on the company's long-term growth prospects, business model, and technology differentiation in the competitive life sciences tools market. Key areas of focus for investors include recurring revenue generation from instruments and consumables, R&D investment, operational efficiency, and a strong balance sheet to fund growth initiatives.
Cytek Biosciences (NASDAQ: CTKB) adds Chief Legal Officer as reporting insider
Cytek Biosciences (NASDAQ: CTKB) has filed an initial Form 3 insider ownership report for Ilan Feuchtwang, its new Chief Legal Officer and Secretary. This filing formally establishes Feuchtwang as a reporting insider but does not indicate any stock purchases, sales, or other transactions. The Form 3 is an administrative disclosure, initiating his obligation to report future holdings and transactions in company securities.
Enterprise value to revenue forward of Cytek Biosciences, Inc. – NASDAQ:CTKB
This article provides financial information for Cytek Biosciences, Inc. (NASDAQ: CTKB) focusing on its enterprise value to revenue forward metric. The content appears to be a financial data page from TradingView, displaying the company's stock market data and financial details without further analytical text.
Price to earnings forward of Cytek Biosciences, Inc. – NASDAQ:CTKB
This article presents the "Price to earnings forward" value for Cytek Biosciences, Inc. (NASDAQ:CTKB) as part of its financial overview on the TradingView platform. It indicates the period, value, and change metrics for this financial indicator, noting that the data is provided by ICE Data Services and FactSet.
Enterprise value to EBIT forward of Cytek Biosciences, Inc. – NASDAQ:CTKB
The article discusses the Enterprise Value to EBIT (EV/EBIT) forward metric for Cytek Biosciences, Inc. (NASDAQ: CTKB). It appears to be an excerpt from a financial data platform, likely TradingView, presenting a specific financial ratio for the company.
Enterprise value to revenue forward of Cytek Biosciences, Inc. – BOATS:CTKB
The article focuses on the enterprise value to revenue forward metric for Cytek Biosciences, Inc. (CTKB) as listed on the Blue Ocean Alternative Trade System (BOATS). It presents financial overview, news, community insights, forecasts, and seasonal trends related to the company's stock data. The content is primarily a data page from TradingView, offering various tools and features for market analysis.
CTKB Forecast — Price Target — Prediction for 2027
The article provides a forecast for Cytek Biosciences, Inc. (CTKB) stock, including analyst price targets and ratings. It details current stock performance, historical highs and lows, and key financial metrics like revenue, earnings, and market capitalization. The article also addresses frequently asked questions about CTKB's stock, such as volatility, dividend policy, and future earnings reports.
8EQ Forecast — Price Target — Prediction for 2027
This article provides an overview of Cytek Biosciences, Inc. (8EQ) stock, including analyst price targets, financial estimates, and historical performance. It details the company's next earnings report date, past earnings and revenue figures, net income, and confirms that it does not pay dividends. The article also includes details about the company's employee count and EBITDA.
Cytek Biosciences, Inc. Actuals & Estimates (NASDAQ:CTKB)
This article provides an overview of Cytek Biosciences, Inc. (NASDAQ:CTKB) stock performance, financial data, and analyst forecasts. It covers current stock price, historical highs and lows, volatility, market capitalization, and upcoming earnings reports, along with frequently asked questions about investing in CTKB.
Cytek Biosciences, Inc. Actuals & Estimates (SWB:8EQ)
This article provides an overview of Cytek Biosciences, Inc. (SWB:8EQ) stock, including financial actuals and estimates for income, balance sheet, and cash flow. It also details analyst price targets, historical stock performance, upcoming earnings dates, and financial metrics like revenue, net income, and EBITDA. The company does not pay dividends and has 700 employees as of June 26, 2026.
Cytek Biosciences, Inc. Actuals & Estimates (GETTEX:8EQ)
This article provides an overview of Cytek Biosciences, Inc. (GETTEX:8EQ) including its current stock price, market capitalization, financial performance, and analyst forecasts. The stock has shown recent growth, and analysts have set a price target range for its future performance. The article also provides historical data like all-time high/lows and details on volatility, earnings, revenue, and EBITDA.
Cytek Biosciences (NASDAQ: CTKB) legal chief exit detailed
Cytek Biosciences (NASDAQ: CTKB) has
Cytek Biosciences' Valerie Barnett to Depart as Chief Legal Officer and Corporate Secretary
Valerie Barnett will step down from her role as Chief Legal Officer and Corporate Secretary of Cytek Biosciences, effective June 29, 2026. The company stated that her departure is not due to any disagreement with its operations, policies, or practices. Specific details regarding a replacement were not disclosed.
Cytek Biosciences, Inc. Announces Termination of Valerie Barnett as Chief Legal Officer and Corporate Secretary, Effective June 29, 2026
Cytek Biosciences, Inc. announced the termination of Valerie Barnett's position as Chief Legal Officer and Corporate Secretary, effective June 29, 2026. The company stated that Ms. Barnett's separation is not due to any disagreement with Cytek Biosciences' operations, policies, or practices. The agreement for her departure was reached on June 18, 2026.
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P Composite 1500
Cytek Biosciences, Inc. (NasdaqGS: CTKB) has been removed from the S&P Composite 1500 index. The announcement was made on June 21, 2026, at 08:57 pm EDT. The article also provides recent news updates about Cytek Biosciences, including board appointments, product innovations, and financial results.
Cytek Biosciences Stockholders Back Board, Pay and Auditor
Cytek Biosciences (CTKB) stockholders recently held their 2026 annual meeting, with strong investor participation. They re-elected three Class II directors, approved executive compensation, and ratified Deloitte & Touche LLP as the independent accounting firm, ensuring continuity in governance and financial oversight. An analyst from TipRanks has a "Buy" rating on CTKB, though TipRanks' AI Analyst, Spark, rates it as "Neutral" due to weak financial performance and a bearish technical setup.
Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets
Cytek Biosciences (CTKB) has seen its modelled fair value and average analyst price target reduced due to high operating expenses and an EBITDA shortfall. Despite these cuts, some analysts maintain an Overweight rating citing attractive valuation and potential M&A interest, while cautious voices suggest waiting for clearer cost progress. The company plans to showcase new cell analysis solutions and reaffirms its 2026 revenue guidance.
Cytek Biosciences (CTKB) CTO Yan Ming reports bona fide gift of shares
Cytek Biosciences' Chief Technology Officer, Yan Ming, reported a bona fide gift of 135,892 shares of common stock. This transaction, indicated by a Form 4 filing, involved no monetary exchange ($0.00 price per share) and was a non-market transfer. Following the gift, Ming retains 4,796,688 shares of common stock directly, making the gifted amount a relatively small portion of his total holdings.
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Cytek Biosciences Inc (CTKB) as of FY2023. It categorizes revenue by business segments, showing that Biotechnology, pharmaceutical, distributor, and CRO contributed 57.93% and Academia and government contributed 42.07%. The report also breaks down revenue by region, with the United States accounting for 47.27%, EMEA 27.73%, APAC 20.39%, and Other regions 4.61%.
Cytek Biosciences shareholders elect directors and approve key proposals at annual meeting
Cytek Biosciences (NASDAQ:CTKB) held its 2026 annual meeting where shareholders elected three Class II directors, approved executive compensation, and ratified Deloitte & Touche LLP as the independent auditor. The company, with a market cap of $526.9 million, is considered undervalued by InvestingPro. In related news, Cytek Biosciences recently reported a 6% increase in Q1 2026 revenue to $44.1 million, though its EPS loss of $0.15 exceeded expectations due to higher operating expenses.
Cytek Biosciences (CTKB) details 2026 shareholder meeting voting outcomes
Cytek Biosciences (CTKB) reported the outcomes of its 2026 annual shareholder meeting held on June 10, 2026. A strong quorum of approximately 86.1% of eligible shares was established. Shareholders approved three director nominees and two additional proposals with significant "for" votes.
CTKB: FY26 Guidance And Potential Takeout Interest May Support Future Upside
Cytek Biosciences (CTKB) has seen its average price target trimmed by analysts due to elevated operating expenses and an EBITDA shortfall, but valuation and potential M&A interest are noted as supporting factors. The company reaffirmed its 2026 revenue guidance and plans to showcase new cell analysis solutions. Despite a slight reduction in fair value, the reiteration of guidance is seen as positive for confidence in the company's growth trajectory.
Cytek Biosciences (CTKB) Singular Research’s Las Vegas Invitational Conference summary
Cytek Biosciences (CTKB) presented at Singular Research’s Las Vegas Invitational Conference, highlighting its leadership in cell analysis with nearly 4,000 systems placed and a strong financial position with $262.2 million in cash. The company emphasized its pioneering Full Spectrum technology, the launch of Borealis, and a projected addressable market of $9.2 billion by 2032, driven by instruments, recurring revenue from reagents/services, bioinformatics, and clinical applications.
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity
Cytek Biosciences director Glenn P. Muir reported receiving equity awards, including a stock option for 29,835 shares with an exercise price of $4.05 and 55,555 restricted stock units (RSUs). These compensation grants, not open-market trades, will vest over time, increasing his potential ownership in the company. The stock option vests monthly over three years, while the RSUs vest in tranches between August 2026 and August 2027, contingent on continued service.
Cytek Biosciences (CTKB) director boosts stake with RSU exercise and new option, RSU grants
Cytek Biosciences director Imper Vera increased her equity stake through compensation awards. On June 10, 2026, she exercised 43,973 vested Restricted Stock Units, receiving an equal number of common shares and bringing her direct common stock holdings to 59,679 shares. She also received new grants of 18,261 director stock options and 33,333 Restricted Stock Units, both vesting on the earlier of June 10, 2027, or the company's 2027 annual meeting.
Cytek Biosciences (CTKB) director Glenn Muir files initial ownership report
Cytek Biosciences (CTKB) director Glenn P. Muir has filed an initial Form 3 beneficial ownership report, designating him as a director of the company. The filing indicates no share purchases, sales, or derivative transactions, meaning no changes to his beneficial ownership were reported at this time. This Form 3 acts as an initial disclosure of his position as an insider.
Cytek Biosciences (CTKB) director awarded 18,261 options plus 33,333 RSUs
Cytek Biosciences director Richard Chin received equity awards comprising 18,261 stock options with an exercise price of $4.05 and 33,333 restricted stock units (RSUs) as part of his board compensation. Both awards are set to vest 100% on the earlier of June 10, 2027, or the company’s 2027 annual stockholder meeting, provided it occurs in June 2027. These grants are compensatory and do not involve open-market transactions.
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
Cytek Biosciences (Nasdaq: CTKB) announced its participation in Singular Research's Las Vegas Invitational Conference from June 14-16, 2026. Management is scheduled to present on June 15th at 11:00 a.m. Pacific Time, with a live and archived webcast available on the company's investors section. Cytek Biosciences is a cell analysis solutions company known for its Full Spectrum Profiling™ (FSP®) technology.
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in Singular Research's Las Vegas Invitational Conference from June 14-16, 2026. Cytek management is scheduled to present on June 15th at 11:00 a.m. Pacific Time, with a live and archived webcast accessible on the company's investors section. The company specializes in advanced cell analysis solutions using its patented Full Spectrum Profiling™ (FSP®) technology.
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in Singular Research's Las Vegas Invitational Conference from June 14-16, 2026. Cytek management will present on June 15th at 11:00 a.m. Pacific Time, with a live and archived webcast available on the company's investor website. The company specializes in cell analysis solutions using its patented Full Spectrum Profiling™ technology.
Cytek Biosciences unveils next-generation spectral flow cytometry innovations at CYTO 2026
Cytek Biosciences unveiled its new 7-laser Cytek Borealis™ full spectrum flow cytometer with Deep Ultraviolet (DUV) and Infrared (IR) cFluor® reagents at CYTO 2026. The company also introduced enhanced automation-ready configurations for its Cytek Aurora Evo system. These innovations aim to expand high-parameter cytometry, automation, and workflow efficiency for cell analysis in research and biopharma.
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences will introduce its new 7-laser Cytek Borealis™ system and enhancements to the Cytek Aurora™ Evo system at CYTO 2026. The Borealis system integrates full spectrum flow cytometry with future cellular imaging capabilities and includes Deep Ultraviolet (DUV) and Infrared (IR) cFluor® reagents for expanded signal detection. The Aurora Evo enhancements focus on automation and workflow efficiency, making it suitable for large-scale studies in biopharma and contract research organizations.
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences will showcase its latest spectral flow cytometry innovations at CYTO 2026, including the new 7-laser Cytek Borealis system, which integrates full spectrum flow cytometry with future cellular imaging capabilities. The company will also highlight enhancements to the Cytek Aurora Evo system for improved automation and workflow efficiency. These developments aim to expand high-parameter analysis and offer researchers more comprehensive cell analysis tools.
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences will showcase its latest advancements in spectral flow cytometry at CYTO 2026, including the public debut of the new 7-laser Cytek Borealis system, which integrates full spectrum flow cytometry with future cellular imaging capabilities. The company will also highlight automation-ready configurations for its Cytek Aurora Evo system, designed to enhance workflow efficiency and scalability in automated environments. These innovations aim to provide researchers with more flexible, scalable, and insightful cell analysis solutions for high-parameter studies.
Cytek Biosciences, Inc. Announces Resignation of Philippe Busque from Senior Vice President, Global Sales and Services, Effective June 5, 2026
Cytek Biosciences, Inc. announced that Philippe Busque has resigned from his position as Senior Vice President, Global Sales and Services, effective June 5, 2026. Dr. Busque is leaving to pursue another career opportunity, and his resignation is not due to any disagreement with the Company's operations, policies, or practices. The announcement was made via an S&P Capital IQ SEC Form 8k.
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences will showcase its new 7-laser Cytek Borealis full spectrum flow cytometer and enhancements to the Cytek Aurora Evo system at CYTO 2026. The Borealis system integrates full spectrum flow cytometry with future cellular imaging capabilities, offering 120 detectors and Deep Ultraviolet (DUV) and Infrared (IR) lasers for high-resolution 60-color panels. The Aurora Evo updates aim to improve automation and workflow efficiency for large-scale studies in biopharma and CROs.
Inside Cytek's 7-laser machine aiming for 60-color views of cells
Cytek Biosciences will debut its new 7-laser Cytek Borealis full spectrum flow cytometer and automation-ready Cytek Aurora Evo configurations at CYTO 2026. The Borealis system features 120 detectors and DUV/IR lasers, enabling high-resolution 60-color panels and future cellular imaging capabilities. These innovations aim to expand high-parameter analysis, increase automation, and provide deeper biological insights for researchers, particularly in biopharma and CROs.
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences will showcase its latest spectral flow cytometry innovations at CYTO 2026, including the public debut of the 7-laser Cytek Borealis system, which incorporates Deep Ultraviolet and Infrared lasers and imaging capabilities. The company will also highlight new automation and workflow efficiency enhancements for its Cytek Aurora Evo system. These advancements aim to provide researchers with expanded capabilities for high-parameter cell analysis and improved integration into automated laboratory environments.
Cytek Biosciences' Philippe Busque resigns as Senior VP, Global Sales and Services
Philippe Busque has resigned from his position as Senior Vice President, Global Sales and Services at Cytek Biosciences (CTKB), effective June 5, 2026. His resignation is to pursue another career opportunity and is not due to any disagreement with the company's operations. No replacement information has been disclosed.
Cytek Biosciences (CTKB) SVP Global Sales and Services to step down June 5, 2026
Cytek Biosciences (CTKB) announced that Philippe Busque, Ph.D., Senior Vice President, Global Sales and Services, will resign effective June 5, 2026. According to an 8-K filing, his departure is to pursue another career opportunity and is not due to any disagreements with the company's operations, policies, or practices. The resignation date was May 27, 2026, and the 8-K report was signed on June 2, 2026.
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences will showcase its latest spectral flow cytometry innovations at CYTO 2026, including the public debut of the new 7-laser Cytek Borealis full spectrum flow cytometer and enhanced automation features for the Cytek Aurora Evo system. The Cytek Borealis integrates full spectrum flow cytometry with future cellular imaging capabilities and supports high-resolution 60-color panels. These advancements aim to provide researchers with greater flexibility, scalability, and insights for high-parameter cell analysis.
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Cytek Biosciences is scheduled to report its first-quarter 2026 financial results after market close on May 7, 2026. The company will also host a conference call and webcast on the same day to discuss these results.
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming
This article from Moomoo Investments is a brief announcement regarding a statement of changes in beneficial ownership of securities for Cytek Biosciences, specifically pertaining to Officer Yan Ming. The content primarily states that the full announcement is available as a separate document, Doc 1. It also includes extensive disclaimers about investment information and promotion of Moomoo's services across various regions.
Cytek Biosciences (CTKB) CTO vests RSUs, holds 4,919,617 shares
Cytek Biosciences' Chief Technology Officer, Yan Ming, reported routine equity compensation activity involving the exercise of 22,179 restricted stock units (RSUs) into common stock. To cover tax obligations, 5,532 shares were withheld by the company at $3.55 per share. Following these transactions, Yan Ming directly owns 4,919,617 shares of Cytek common stock.
Cytek Biosciences (Nasdaq:CTKB) - Stock Analysis
Cytek Biosciences (Nasdaq:CTKB) is a cell analysis solutions company providing tools for biomedical research. The company is currently unprofitable and its EPS estimates have recently fallen. However, analysts see undervaluation and future growth potential driven by new product launches, European expansion, and recurring revenue streams.
Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting
Cytek Biosciences director Michael Holder acquired 1,454 shares of common stock on May 18, 2026, through the exercise and conversion of restricted stock units (RSUs). This transaction was part of a routine equity compensation event and not an open-market purchase. Following this, Holder directly holds 16,721 common shares and 9,457 RSUs which will vest in tranches until August 2025.
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock
Cytek Biosciences director Richard Chin converted 6,107 Restricted Stock Units (RSUs) into an equal number of common stock shares on May 18, 2026, at a price of $0.00 per share. Following this transaction, Chin directly holds 22,392 common stock shares and 50,897 RSUs. The RSU award vests in multiple tranches through August 18, 2026.
Cytek Biosciences (CTKB) SVP nets shares after RSU vesting and tax withholding
Cytek Biosciences SVP Philippe Busque exercised awards for 10,464 shares of common stock from vested restricted stock units on May 18, 2026. To cover tax withholding, 2,685 shares were surrendered back to the company at $3.55 per share. Following these transactions, Busque directly holds 36,448 shares of Cytek Biosciences common stock and 5,641 unvested restricted stock units.
Cytek Biosciences (CTKB) CLO gains shares after RSU vesting
Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported the exercise of 24,295 Restricted Stock Units (RSUs) into common shares on May 18, 2026. A total of 8,719 shares were withheld at $3.55 per share to cover tax obligations, which is a routine compensation-related transaction and not an open-market sale. After these transactions, Barnett directly holds 136,009 common shares and retains 12,280 RSUs.
